Publications

The forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-containing histone deubiquitinase complex.

Authors: Z Ji, H Mohammed, A Webber, J Ridsdale, N Han, JS Carroll, AD Sharrocks

E-pub date: 1 Jun 2014

Journal name: Nucleic Acids Res

THE TOLL-LIKE RECEPTOR PATHWAY IS RECURRENTLY MUTATED IN OESOPHAGEAL ADENOCARCINOMA

Authors: DRF Elliott, CS Ross-Innes, MD Eldridge, RC Fitzgerald

E-pub date: 1 Jun 2014

Journal name: Gut

PTU-153 The Timing Of Oncogenic Events In The Evolution Of The Oesophageal Adenocarcinoma Genome And Implications For Clinical Diagnostics.

Authors: J Weaver, C Ross-Innes, N Shannon, A Lynch, M Murtaza, T Forshew, M Dunning...

E-pub date: 1 Jun 2014

Journal name: Gut

USP28 is recruited to sites of DNA damage by the tandem BRCT domains of 53BP1 but plays a minor role in double-strand break metabolism.

Authors: PA Knobel, R Belotserkovskaya, Y Galanty, CK Schmidt, SP Jackson, TH Strack...

E-pub date: 1 Jun 2014

Journal name: Mol Cell Biol

Addendum: Quantitative sequencing of 5-formylcytosine in DNA at single-base resolution.

Authors: MJ Booth, G Marsico, M Bachman, D Beraldi, S Balasubramanian

E-pub date: 21 May 2014

Journal name: Nat Chem

ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.

Authors: EM Swisher, IA McNeish, RL Coleman, J Brenton, SH Kaufmann, AR Allen, M Rap...

E-pub date: 20 May 2014

Journal name: Journal of Clinical Oncology

A national platform for molecular diagnostics: Results of the Cancer Research UK Stratified Medicine Programme

Authors: E Shaw, R Butler, DG de Castro, M Griffiths, A Hanby, J Hair, F Rae, J Roga...

E-pub date: 20 May 2014

Journal name: Journal of Clinical Oncology

ICON8: An international randomized trial comparing two dose dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carhoplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer

Authors: J Hook, SP Stenning, J Brenton, SB Kaye, IA McNeish, R Naik, T Perron, J Pe...

E-pub date: 20 May 2014

Journal name: Journal of Clinical Oncology

Filters

Research Groups

Core Facilities

Start date

End date

The forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-containing histone deubiquitinase complex.

THE TOLL-LIKE RECEPTOR PATHWAY IS RECURRENTLY MUTATED IN OESOPHAGEAL ADENOCARCINOMA

PTU-153 The Timing Of Oncogenic Events In The Evolution Of The Oesophageal Adenocarcinoma Genome And Implications For Clinical Diagnostics.

USP28 is recruited to sites of DNA damage by the tandem BRCT domains of 53BP1 but plays a minor role in double-strand break metabolism.

Addendum: Quantitative sequencing of 5-formylcytosine in DNA at single-base resolution.

ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.

A national platform for molecular diagnostics: Results of the Cancer Research UK Stratified Medicine Programme

ICON8: An international randomized trial comparing two dose dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carhoplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer

Themes

Filters

Research Groups

Core Facilities

Start date

End date

The forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-containing histone deubiquitinase complex.

THE TOLL-LIKE RECEPTOR PATHWAY IS RECURRENTLY MUTATED IN OESOPHAGEAL ADENOCARCINOMA

PTU-153 The Timing Of Oncogenic Events In The Evolution Of The Oesophageal Adenocarcinoma Genome And Implications For Clinical Diagnostics.

USP28 is recruited to sites of DNA damage by the tandem BRCT domains of 53BP1 but plays a minor role in double-strand break metabolism.

Addendum: Quantitative sequencing of 5-formylcytosine in DNA at single-base resolution.

ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.

A national platform for molecular diagnostics: Results of the Cancer Research UK Stratified Medicine Programme

ICON8: An international randomized trial comparing two dose dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carhoplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer